407 related articles for article (PubMed ID: 32979150)
1. Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer.
Broberg AM; Geisler J; Tuohinen S; Skytta T; Hrafnkelsdóttir ÞJ; Nielsen KM; Hedayati E; Omland T; Offersen BV; Lyon AR; Gulati G
Curr Heart Fail Rep; 2020 Dec; 17(6):397-408. PubMed ID: 32979150
[TBL] [Abstract][Full Text] [Related]
2. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Rygiel K
Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
[TBL] [Abstract][Full Text] [Related]
3. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.
Jain D; Russell RR; Schwartz RG; Panjrath GS; Aronow W
Curr Cardiol Rep; 2017 May; 19(5):36. PubMed ID: 28374177
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of cancer chemotherapy in clinical practice.
Jain D; Aronow W
Hosp Pract (1995); 2019 Feb; 47(1):6-15. PubMed ID: 30270693
[TBL] [Abstract][Full Text] [Related]
6. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer and Heart Failure.
Almuwaqqat Z; Meisel JL; Barac A; Parashar S
Heart Fail Clin; 2019 Jan; 15(1):65-75. PubMed ID: 30449381
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?
Caron J; Nohria A
Curr Oncol Rep; 2018 Jun; 20(8):61. PubMed ID: 29876677
[TBL] [Abstract][Full Text] [Related]
9. Left Ventricular Dysfunction and Chemotherapeutic Agents.
Clasen SC; Wald JW
Curr Cardiol Rep; 2018 Mar; 20(4):20. PubMed ID: 29520629
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
[TBL] [Abstract][Full Text] [Related]
11. Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review.
Jafari L; Akhter N
Breast Cancer Res Treat; 2021 Apr; 186(2):295-303. PubMed ID: 33481134
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
13. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
14. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
[TBL] [Abstract][Full Text] [Related]
16. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
Blanter JB; Frishman WH
Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy.
Chen DH; Tyebally S; Malloupas M; Roylance R; Spurrell E; Raja F; Ghosh AK
Curr Cardiol Rep; 2021 Jan; 23(3):16. PubMed ID: 33501515
[TBL] [Abstract][Full Text] [Related]
18. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
20. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
